Abstract
Acute kidney injury (AKI) is a syndrome characterized by an acute renal cell injury that leads to sudden loss of renal function. There are currently no clinically validated treatments for AKI besides substituting renal function by dialysis. However, new biomarkers will allow an earlier diagnosis, thus providing a window of opportunity for therapeutic intervention. Acute kidney injury (AKI) is a syndrome characterized by an acute renal cell injury that leads to sudden loss of renal function. There are currently no clinically validated treatments for AKI besides substituting renal function by dialysis. However, new biomarkers will allow an earlier diagnosis, thus providing a window of opportunity for therapeutic intervention. We review the potential role of tyrphostins in the prophylaxis and treatment of acute kidney injury on the basis of published studies on animals, in vitro experiments and piecemeal information from humans. The AG 490 and AG 126 tyrphostins have recently been shown to protect from AKI in experimental animal models of ischemia-reperfusion and sepsis-induced injury. AG 490 protects from cyclosporin-induced AKI and AG 1714 protects from cisplatin nephrotoxicity. AG 490 is nephroprotective by inhibiting oxidative stress-related Janus activated kinase-2 (JAK2) activation. Potential applications of AG490 or derivative molecules include AKI of nephrotoxic or ischemic nature, or a combination of both, as may occur in the immediate postransplant period. The molecular targets of AG 126 and AG 1714 are less well characterized. In conclusions, different tyrphostins are nephroprotective in animal models of AKI. The characterization of the molecular targets involved will allow the design of novel therapies that may reach the clinical trial stage.
Keywords: Acute kidney injury, protein tyrosine kinases, tyrphostins, ischemia-reperfusion, sepsis, cisplatin, cyclosporine, nephroprotection
Current Medicinal Chemistry
Title: Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Volume: 17 Issue: 10
Author(s): S. Goncalves, R. Fernandez-Sanchez, M. D. Sanchez-Nino, A. Tejedor, F. Neria, J. Egido, M. Ruiz-Ortega and A. Ortiz
Affiliation:
Keywords: Acute kidney injury, protein tyrosine kinases, tyrphostins, ischemia-reperfusion, sepsis, cisplatin, cyclosporine, nephroprotection
Abstract: Acute kidney injury (AKI) is a syndrome characterized by an acute renal cell injury that leads to sudden loss of renal function. There are currently no clinically validated treatments for AKI besides substituting renal function by dialysis. However, new biomarkers will allow an earlier diagnosis, thus providing a window of opportunity for therapeutic intervention. Acute kidney injury (AKI) is a syndrome characterized by an acute renal cell injury that leads to sudden loss of renal function. There are currently no clinically validated treatments for AKI besides substituting renal function by dialysis. However, new biomarkers will allow an earlier diagnosis, thus providing a window of opportunity for therapeutic intervention. We review the potential role of tyrphostins in the prophylaxis and treatment of acute kidney injury on the basis of published studies on animals, in vitro experiments and piecemeal information from humans. The AG 490 and AG 126 tyrphostins have recently been shown to protect from AKI in experimental animal models of ischemia-reperfusion and sepsis-induced injury. AG 490 protects from cyclosporin-induced AKI and AG 1714 protects from cisplatin nephrotoxicity. AG 490 is nephroprotective by inhibiting oxidative stress-related Janus activated kinase-2 (JAK2) activation. Potential applications of AG490 or derivative molecules include AKI of nephrotoxic or ischemic nature, or a combination of both, as may occur in the immediate postransplant period. The molecular targets of AG 126 and AG 1714 are less well characterized. In conclusions, different tyrphostins are nephroprotective in animal models of AKI. The characterization of the molecular targets involved will allow the design of novel therapies that may reach the clinical trial stage.
Export Options
About this article
Cite this article as:
Goncalves S., Fernandez-Sanchez R., Sanchez-Nino D. M., Tejedor A., Neria F., Egido J., Ruiz-Ortega M. and Ortiz A., Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury, Current Medicinal Chemistry 2010; 17 (10) . https://dx.doi.org/10.2174/092986710790820642
DOI https://dx.doi.org/10.2174/092986710790820642 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brief Review of Polymorphic Drug-Metabolizing Enzymes in Japanese Populations: Development of a Higher-Throughput Genotyping Method and Proposed Applications
Drug Metabolism Letters Contribution and Value of Biomarkers in Acute Aortic Syndromes
Current Pharmaceutical Biotechnology Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?
Current Medicinal Chemistry Acute Phase Treatment of Pulmonary Embolism
Current Vascular Pharmacology B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Current Molecular Medicine Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety Microcirculatory Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Isolation and Purification of Kudinosides from Kuding Tea by Semi-Preparative HPLC Combined with MCI-GEL Resin
Current Analytical Chemistry Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Nitrergic Modulation of Gastrointestinal Function During Early Endotoxemia
Current Pharmaceutical Design A Comparative Effectiveness Systematic Review and Meta-analysis of Drugs for the Prophylaxis of Junctional Ectopic Tachycardia
Current Cardiology Reviews Editorial (Current Thought in Perinatal Haemodynamics)
Current Pediatric Reviews Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease
Current Vascular Pharmacology Stereospecific Synthesis of m-Hydroxymexiletine Enantiomers
Drug Metabolism Letters Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features
Current Cardiology Reviews Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Decreasing Arterial Aging by Controlling Blood Pressure Levels and Hypertension: A Step Forward
Current Vascular Pharmacology